Home>>Lipids>> Sphingolipids>>C22 Glucosylceramide (d18:1/22:0)

C22 Glucosylceramide (d18:1/22:0) (Synonyms: N-C22:0-Glucocerebroside, C22 Glucosylceramide, GluCer(18:1/22:0), Glucosylceramide (d18:1/22:0, N-Docosanoyl-β-glucosylsphingosine, N-Docosanoyl-glucopsychosine)

Catalog No.GC43070

C22 Glucosylceramide (d18:1/22:0) is an endogenous glucosylceramide.

Products are for research use only. Not for human use. We do not sell to patients.

C22 Glucosylceramide (d18:1/22:0) Chemical Structure

Cas No.: 119242-44-3

Size Price Stock Qty
1mg
$762.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

C22 Glucosylceramide (d18:1/22:0) is an endogenous glucosylceramide. Glucosylceramides are major constituents of skin lipid membranes where they play a role in maintaining the water permeability barrier. They are precursors in the synthesis of lactosylceramide , as well as oligoglycolipids and gangliosides. Phospholipase A2 (PLA2) type XIIA knockdown increases C22 glucosylceramide (d18:1/22:0) expression in rat brain. It is also increased in the brain, but not the liver or spinal cord, of mice fed a methionine-restricted diet. In human athletes, plasma levels of C22 glucosylceramide (d18:1/22:0) increase during exercise and return to basal levels during recovery. This product contains C22 glucosylceramide (d18:1/22:0) isolated from bovine buttermilk.

Reviews

Review for C22 Glucosylceramide (d18:1/22:0)

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for C22 Glucosylceramide (d18:1/22:0)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.